Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis

Journal of Medicinal Chemistry

Volumn 50, Issue 24, 2007, Pages 6095-6103

  Bunnage, Mark E ^a   Blagg, Julian ^a   Steele, John ^a   Owen, Dafydd R ^a   Allerton, Charlotte ^a   McElroy, Andrew B ^a   Miller, Duncan ^a   Ringer, Tracy ^a   Butcher, Ken ^a   Beaumont, Kevin ^a   Evans, Karen ^a   Gray, Andrew J ^a   Holland, Stephen J ^a   Feeder, Neil ^a   Moore, Robert S ^a   Brown, David G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2 [(1 N PROPYL 1H IMIDAZOL 4 YL)METHYL]PENTANOIC ACID; ARGININE CARBOXYPEPTIDASE; FIBRIN; IMIDAZOLE DERIVATIVE; PROPIONIC ACID DERIVATIVE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UK 396 082; UNCLASSIFIED DRUG; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING; CATALYST; CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; FIBRINOLYSIS; HUMAN; HYDROPHILICITY; MALE; MOLECULAR WEIGHT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL CHEMISTRY; RABBIT; STRUCTURE ACTIVITY RELATION; THROMBOSIS; VEIN THROMBOSIS; X RAY CRYSTALLOGRAPHY;

AMINO ACIDS; ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; BLOOD LOSS, SURGICAL; CARBOXYPEPTIDASE B; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DOGS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; IMIDAZOLES; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PANCREAS; RABBITS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 37849034911     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0702433     Document Type: Article

References (43)

1. Bajzar, L.; Manuel, R.; Nesheim, M. E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 1995, 270, 14477-14484.
2. (a) Nesheim, M. E. TAFI. Fibrinolysis Proteolysis 1999, 13, 72-77.
3. (b) Nesheim, M.; Wang, W.; Boffa, M.; Nagashima, M.; Morser, J.; Bajzar, L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb. Haemostasis 1997, 78, 386-391.
4. For recent reviews on TAFI, see: (a) Willemse, J. L.; Hendriks, D. F. A role for procarboxypeptidase U (TAFI) in thrombosis. Front. Biosci. 2007, 12, 1973-1987.
5. (b) Mosnier, L. O.; Bouma, B. N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler., Thromb., Vasc. Biol. 2006, 26, 2445-2453.
6. (b) Marx, P. F. Thrombin-activatable fibrinolysis inhibitor. Curr. Med. Chem. 2004, 11, 2335-2348.
7. Eaton, D. L.; Malloy, B. E.; Tsai, S. P.; Henzel, W.; Dryana, D. Isolation, molecular cloning, and partial characterisation of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 1991, 266, 21833-21838.
8. Wang, W.; Hendriks, D. F.; Scharpe S. S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 1994, 269, 15937-15944.
9. Refino, C. J.; DeGuzman, L.; Schmitt, D.; Smyth, R.; Jeet, S.; Lipari, M. T.; Eaton, D.; Bunting, S. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis, and hemostasis. Fibrinolysis Proteolysis 2000, 14, 305-314.
10. Allerton, C. M. N.; Blagg, J.; Bunnage, M. E. Steele, J. PCT Int. Appl. WO 2002014285, 2002.
11. Ondetti, M. A.; Condon, M. E. U.S. Patent 4146611, 1979.
12. Commercially available from Aldrich Chemical Company.
13. Jain, R.; Cohen, L. A. Regiospecific alkylation of histidine and histamine at N-I (τ). Tetrahedron 1996, 52, 5363-5370.
14. Huszthy, P.; Bradshaw, J. S.; Krakowiak, K. E.; Wang, T.; Dalley, N. K. Efficient synthesis of azetidine through N-trityl- or N- dimethoxyttitylazetidines starting from 3-amino-1-propanol or 3-halopropylamine hydrohalides. J. Heterocycl. Chem. 1993, 30, 1197-1207.
15. 3-SnH mediated oxidative radical cyclisafion onto imidazoles and pyrrole. Tetrahedron 1999, 55, 8111-8128.
16. Nansada, M.; Horibe, I.; Watanabe, F.; Takeda, K. Selective reduction of aryl halides and a,b-unsaturated esters with sodium borohydride-cuprous chloride in methanol and its application to deuterium labeling. J. Org. Chem. 1989, 54, 5308-5313.
17. Flynn, D. L.; Zelle, R. E.; Grieco, P. A. A mild two-step method for the hydrolysis/methanolysis of secondary amides and lactams. J. Org. Chem. 1983, 48, 2424-2426.
18. Appleby, I; Boulton, L. T.; Cobley, C. J.; Hill, C.; Hughes, M.; De Koning, P. D.; Lennon, I. C.; Praquin, C.; Ramsden, J. A.; Samuel, H. J.; Willis, N. Efficient synthesis of an imidazole-substituted d-amino acid by the integration of chiral technologies. Org. Lett. 2005, 7, 1931-1934.
19. The potato tuber carboxypeptidase inhibitor peptide (PCI) had been shown to be a potent inhibitor of TAFIa: Bajzar, L.; Nesheim, M. E.; Tracy, P. B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996, 88, 2093-2100.
20. Over recent years, a number of nonpeptidic TAFIa inhibitors have been disclosed, including a related series of imidazole-based inhibitors from Merck; see: (a) Barrow, J. C.; Nantermet, P. G.; Stauffer, S. R.; Ngo, P. L.; Steinbeiser, M. A.; Mao, S.-S.; Carroll, S. S.; Bailey, C.; Colussi, D.; Bosserman, M.; Burlein, C.; Cook, J. J.; Sitko, G.; Tiller, P. R.; Miller-Stein, C. M.; Rose, M.; McMasters, D. R.; Vacca, J. P.; Selnick, H. G. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J. Med. Chem. 2003, 46, 5294-5297.
21. (b) Nantermet, P. G.; Barrow, J. C.; Lindsley, S. R.; Young, M.; Mao, S.-S.; Carroll, S.; Bailey, C.; Bosserman, M.; Colussi, D.; McMasters, D. R.; Vacca, J. P.; Selnick, H. G. Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P1′ group, Bioorg. Med. Chem. Lett. 2004, 14, 2141-2145.
22. Byers, L. D. Wolfenden, R. Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 1973, 12, 2070-2078.
23. Ondetti, M. A.; Condon, M. E.; Reid, J.; Sabo, E. F.; Cheung, H. S.; Cushman, D. W. Design of potent and specific inhibitors of carboxypeptidases A and B. Biochemistry 1979, 18, 1427-1430.
24. Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196, 441-444.
25. Cushman, D. W.; Ondetti, M. A. Inhibitors of angiotensin-converting enzyme. Prog. Med. Chem. 1980, 17, 41-104.
26. Plummer, T. H., Jr.; Ryan, T. J. A potent mercapto bi-product analog inhibitor for human carboxypeptidase N. Biochem. Biophys. Res. Commun. 1981, 98, 448-454.
27. Skidgel, R. A. Basic carboxypeptidases: regulators of peptide hormone activity. TIPS 1988, 9, 299-304.
28. Huey, R.; Bloor, C. M.; Kawahara, M. S.; Hugh, T. E. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathological effects on pulmonary tissue. Am. J. Pathol. 1983, 112, 48-60.
29. Lee, K. J.; Joo, K. C.; Kim, E.-J.; Lee, M.; Kim, D. H. A new type of carboxypeptidase A inhibitors designed using an imidazole as a zinc coordinating ligand. Bioorg. Med. Chem. 1997, 5, 1989-1998.
30. The numbering system used is the same as that used for the deposited structure INSA.
31. Researchers at Merck have also shown the efficacy of TAFIa inhibition in a model of thrombosis in African green monkeys; see ref 17(a). In addition, researchers at Berlex have recently reported in vivo efficacy data for their TAFIa inhibitor, BX 528; see: Wang, Y.-X.; da Cunha, V.; Vincelette, J.; Zhao, L.; Nagashima, M.; Kawai, K.; Yuan, S.; Emayan, K.; Islam, I.; Hosoya, J.; Sullivan, M. E.; Dole, W. P.; Morser, J.; Buckman, B. O.; Vergona, R. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - Part thrombosis. Thromb. Haemost. 2007, 97(1), 54-61.
32. Artursson, P.; Ungell, A.-L.; Löfroth, J. E. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. 1993, 10, 1123-1129.
33. He, Y.-L.; Murby, S.; Warhurst, G.; Gifford, L.; Walker, D.; Ayrton, J.; Eastmond, R.; Rowland, M. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of polyethylene glycol and D-peptides. J. Pharm. Sci. 1998, 87, 626-633.
34. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology; Carter, C. W., Jr, Sweet, R. M., Eds.; Academic Press: New York, 1997; Vol. 276, Part A, pp 307-326.
35. CCP4 suite. Acta Crystallogr. 1994, D50, 760-763.
36. Navaza, J. AMORE. Acta Crystallogr. 1994, A 50, 157-163.
37. Brunger, A. T. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355, 472-475.
38. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A program to check the stereochemical quality of protein structure. J. Appl. Crystallogr. 1993, 26, 283-291.
39. SMART v5.618 (control) and SAINT v6.02 (integration) software; Bruker AXS, Inc.: Madison, WI, 1994.
40. Sheldrick, G. M. SADABS: Program for Scaling and Correction of Area Detector Data; University of Göttingen: Göttingen, Germany, 1997 (based on the method of Blessing, R. H. Acta Cryst. 1995, A51, 33-38).
41. Sheldrick, G. M. SHELXS-97: Program for Crystal Structure Solution; University of Göttingen: Göttingen, Germany, 1997 (release 97-2).
42. Sheldrick, G. M. SHELXL-97: Program for Crystal Structure Refinement; University of Göttingen: Göttingen, Germany, 1997 (release 97-2).
43. Flack, H. D. Acta Cryst. 1983, A39, 876-881.